Akari Therapeutics to Present at Biotech Showcase™ 2023

Rhea-AI Summary

On January 4, 2023, Akari Therapeutics (Nasdaq: AKTX) announced that President and CEO Rachelle Jacques will present at the Biotech Showcase 2023 on January 9 at 9 am ET. The presentation will cover significant updates on two pipeline programs: a Phase 3 trial of nomacopan for treating severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and a pre-clinical program for long-acting PAS-nomacopan targeting geographic atrophy. Akari is focused on therapies for autoimmune and inflammatory diseases.

NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET. The presentation will include progress highlights from Akari’s two priority pipeline programs: a Phase 3 clinical trial of nomacopan, a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), for the treatment of severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and a pre-clinical program investigating long-acting PAS-nomacopan as a potential treatment for geographic atrophy.

About Akari Therapeutics
Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari's lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of complement C5 activation and leukotriene B4 (LTB4) activity. Akari's pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA). Akari has been granted Orphan Drug, Fast Track and Rare Pediatric Disease designations from the FDA for nomacopan for the treatment of pediatric HSCT-TMA. Akari’s pipeline also includes pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.

Investor Contact:
Mike Moyer
LifeSci Advisors
(617) 308-4306
mmoyer@lifesciadvisors.com

Media Contact:
Eliza Schleifstein
Schleifstein PR   
(917) 763-8106
eliza@schleifsteinpr.com

 

FAQ

What will Akari Therapeutics present at Biotech Showcase 2023?

Akari Therapeutics will present an overview of its pipeline programs, including a Phase 3 trial of nomacopan for pediatric HSCT-TMA.

When is the presentation by Akari's CEO scheduled?

Rachelle Jacques will present on January 9, 2023, at 9 am ET.

What are the main focuses of Akari Therapeutics' pipeline?

The pipeline focuses on nomacopan for pediatric HSCT-TMA and long-acting PAS-nomacopan for geographic atrophy.

What clinical designation has Akari Therapeutics received for nomacopan?

Nomacopan has received Orphan Drug, Fast Track, and Rare Pediatric Disease designations from the FDA.

What is nomacopan and its intended use?

Nomacopan is a bispecific inhibitor aimed at treating severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy.